Literature DB >> 9557725

Epidemiology of infection with Epstein-Barr virus types 1 and 2: lessons from the study of a T-cell-immunocompromised hemophilic cohort.

Q Y Yao1, D S Croom-Carter, R J Tierney, G Habeshaw, J T Wilde, F G Hill, C Conlon, A B Rickinson.   

Abstract

In apparent contrast to earlier work on Epstein-Barr virus (EBV) carriage in the general Caucasian population, in vitro virus isolations from human immunodeficiency virus (HIV)-positive male homosexual cohorts have shown frequent examples of multiple EBV infection and an overall prevalence of type 2 EBV strains exceeding 30%. Here we ask to what extent these findings might hold true in another T-cell-immunocompromised cohort, HIV-positive hemophilic patients. Resident EBV strains were rescued within lymphoblastoid cell lines derived from the blood and throat washings of 39 such individuals, using the same in vitro protocols of virus isolation as for the homosexual cohort. A mean of 19 independent cell lines was made per patient, and in each case the resident virus was characterized by PCR-based viral genomic analysis and by immunoblotting to reveal the viral "EBNAprint." By these criteria a significant proportion (14 of 39) of the hemophilic cohort carried more than one EBV strain, suggesting that T-cell impairment does indeed sensitize virus carriers to reinfection with new strains of exogenously transmitted virus. However, the overall incidence of type 2 EBV infection was 10%, which is close to that observed in the earlier work with healthy carriers and substantially lower than that seen in HIV-positive homosexuals. We infer that type 2 EBV is relatively rare in the general Caucasian population but has become endemic in the homosexual community.

Entities:  

Mesh:

Year:  1998        PMID: 9557725      PMCID: PMC109665          DOI: 10.1128/JVI.72.5.4352-4363.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells.

Authors:  M Rowe; H S Evans; L S Young; K Hennessy; E Kieff; A B Rickinson
Journal:  J Gen Virol       Date:  1987-06       Impact factor: 3.891

2.  Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins.

Authors:  M Rowe; L S Young; K Cadwallader; L Petti; E Kieff; A B Rickinson
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

3.  Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells.

Authors:  A B Rickinson; L S Young; M Rowe
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

4.  Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes.

Authors:  D J Moss; A B Rickinson; J H Pope
Journal:  Int J Cancer       Date:  1978-12       Impact factor: 7.396

5.  Association of Epstein-Barr virus types 1 and 2 with acquired immunodeficiency syndrome-related primary central nervous system lymphomas.

Authors:  C J Gunthel; V Ng; M McGrath; B Herndier; B Shiramizu
Journal:  Blood       Date:  1994-01-15       Impact factor: 22.113

6.  Detection of A-type and B-type Epstein-Barr virus in throat washings and lymphocytes.

Authors:  A Apolloni; T B Sculley
Journal:  Virology       Date:  1994-08-01       Impact factor: 3.616

7.  Variation in the sequence of Epstein Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt's lymphomas.

Authors:  K Bhatia; A Raj; M I Guitierrez; J G Judde; G Spangler; H Venkatesh; I T Magrath
Journal:  Oncogene       Date:  1996-07-04       Impact factor: 9.867

8.  Identification of potential hot spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: high frequency of a 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas.

Authors:  K Sandvej; S C Peh; B S Andresen; G Pallesen
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

9.  Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma.

Authors:  M J Boyle; W A Sewell; T B Sculley; A Apolloni; J J Turner; C E Swanson; R Penny; D A Cooper
Journal:  Blood       Date:  1991-12-01       Impact factor: 22.113

10.  Detection of multiple Epstein-Barr viral strains in allogeneic bone marrow transplant recipients.

Authors:  J W Gratama; E T Lennette; B Lönnqvist; M A Oosterveer; G Klein; O Ringdén; I Ernberg
Journal:  J Med Virol       Date:  1992-05       Impact factor: 2.327

View more
  18 in total

1.  CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  S Nikiforow; K Bottomly; G Miller
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.

Authors:  A J Aguirre; E S Robertson
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Novel intertypic recombinants of epstein-barr virus in the chinese population.

Authors:  R S Midgley; N W Blake; Q Y Yao; D Croom-Carter; S T Cheung; S F Leung; A T Chan; P J Johnson; D Huang; A B Rickinson; S P Lee
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders.

Authors:  M Rowe; G Niedobitek; L S Young
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains.

Authors:  J M Brooks; D S Croom-Carter; A M Leese; R J Tierney; G Habeshaw; A B Rickinson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Conservation of Epstein-Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy.

Authors:  Qian Tao; Jie Yang; He Huang; Lode J Swinnen; Richard F Ambinder
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

7.  Comprehensive Transcriptome and Mutational Profiling of Endemic Burkitt Lymphoma Reveals EBV Type-Specific Differences.

Authors:  Yasin Kaymaz; Cliff I Oduor; Hongbo Yu; Juliana A Otieno; John Michael Ong'echa; Ann M Moormann; Jeffrey A Bailey
Journal:  Mol Cancer Res       Date:  2017-05       Impact factor: 5.852

8.  Epstein-barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographic areas.

Authors:  G Habeshaw; Q Y Yao; A I Bell; D Morton; A B Rickinson
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  Epstein-Barr virus: general factors, virus-related diseases and measurement of viral load after transplant.

Authors:  Luciana Cristina Fagundes Gequelin; Irina N Riediger; Sueli M Nakatani; Alexander W Biondo; Carmem M Bonfim
Journal:  Rev Bras Hematol Hemoter       Date:  2011

10.  Multiple Epstein-Barr virus infections in healthy individuals.

Authors:  Dennis M Walling; Abigail L Brown; Wiguins Etienne; Wendy A Keitel; Paul D Ling
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.